CN112552397A - Rotavirus VP7 recombinant protein and application thereof - Google Patents

Rotavirus VP7 recombinant protein and application thereof Download PDF

Info

Publication number
CN112552397A
CN112552397A CN202011228737.0A CN202011228737A CN112552397A CN 112552397 A CN112552397 A CN 112552397A CN 202011228737 A CN202011228737 A CN 202011228737A CN 112552397 A CN112552397 A CN 112552397A
Authority
CN
China
Prior art keywords
protein
delta
sequence
rotavirus
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202011228737.0A
Other languages
Chinese (zh)
Other versions
CN112552397B (en
Inventor
张莉莉
方荣祥
宋直钰
谢传淼
霍岩
张玉满
瞿维欢
刘超仁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhilian Shanghai Biotechnology Co ltd
Original Assignee
Zhilian Shanghai Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhilian Shanghai Biotechnology Co ltd filed Critical Zhilian Shanghai Biotechnology Co ltd
Priority to CN202011228737.0A priority Critical patent/CN112552397B/en
Publication of CN112552397A publication Critical patent/CN112552397A/en
Application granted granted Critical
Publication of CN112552397B publication Critical patent/CN112552397B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention discloses a rotavirus VP7 recombinant protein and application thereof, wherein the VP7 recombinant protein is a truncation of an amino acid sequence described in a sequence 2, and the truncation does not contain a sequence at the 284-322 th site in the sequence 2. The antibody Δ VP7 obtained by immunizing rabbits with the VP7 recombinant protein (Δ VP7) was tested for a protective titer of neutralizing antibody against infection of rotavirus RF strain (G6P [1 ]) of 1: 21.97. The VP7 recombinant protein provides a molecular basis for designing a recombinant subunit vaccine through the antigen and preventing the infection of HRV epidemic strains at the present stage.

Description

Rotavirus VP7 recombinant protein and application thereof
Technical Field
The invention belongs to the technical field of biology, and relates to a rotavirus delta VP7 non-cytotoxic recombinant protein and application thereof.
Background
Rotavirus (RV) is a main cause of severe diarrhea of infants, about hundreds of thousands of cases of infant death are caused each year, and vaccination is the only effective prevention and control means. RV vaccines currently on the market are all oral live attenuated vaccines, which are listed by the WHO as "vaccines with process needs improvement" due to their potential risk of intussusception. The subunit vaccine is prepared by taking protective antigen of virus as a core and adjuvant, has good safety and can stimulate the organism to generate enough immunity. Meanwhile, the subunit vaccine can realize accurate immunity to the circulating strains and deal with the rapid variation of RV.
The major neutralizing antigens of RV are VP7(G protein) and VP4(P protein), and at least 27G genotypes have been identified. The molecular flow of human rotavirus RV (HRV) in China is staged, G1 is the main epidemic G type (74.3%) before 2000, G3 (45.2%) is the main epidemic G type, and G1 (21.3%) is the main epidemic G type after 2000 and 2012. From 2012 onwards, RV type G9 was identified as the currently predominant strain prevalent in China. It is worth noting that according to the clade characteristics of the VP7 gene (G9-I-G9-VI), the current epidemic strain is G9-VI (accounting for 96.5%), which is different from the G9-I in the early nineties in China and the widely epidemic G9-III in foreign countries. Whether these circulating strains alter the pathogenicity of humans and whether existing vaccines produce good protection needs further investigation. Designing subunit vaccines according to the VP7 sequence of an epidemic strain is one of the strategies for realizing accurate immunity, but the development process is limited by cytotoxicity caused by full-length expression of the VP7 gene.
Disclosure of Invention
The invention aims to obtain a nontoxic delta VP7 sequence from escherichia coli by taking an HRV epidemic strain BJ-Q794 of Beijing at the present stage as a target strain, thereby providing a potential candidate vaccine for HRV prevention and control.
The invention provides a protein, which is A1) or A2):
A1) VP7 recombinant protein, wherein the VP7 recombinant protein is a short truncation of the amino acid sequence described in sequence 2, and the short truncation does not contain the sequence at position 284-322 in sequence 2;
A2) a1) at the N-terminus or/and the C-terminus.
The amino acid sequence of the VP7 recombinant protein is shown as 51-283 in the sequence 2.
The invention also provides a biomaterial related to the VP7 recombinant protein, which is shown in any one of the following B1) -B5):
B1) a nucleic acid molecule encoding the protein;
B2) an expression cassette comprising the nucleic acid molecule of B1);
B3) a recombinant vector containing the nucleic acid molecule of B1) or a recombinant vector containing the expression cassette of B2);
B4) a recombinant microorganism containing B1) the nucleic acid molecule, or a recombinant microorganism containing B2) the expression cassette, or a recombinant microorganism containing B3) the recombinant vector;
B5) a transgenic animal cell line containing the nucleic acid molecule according to B1) or a transgenic animal cell line containing the expression cassette according to B2).
B1) is a DNA molecule shown in the 151 th-849 th site of the sequence 1 in the sequence table.
The application of the protein disclosed by the invention in any one of the following P1-P3 also belongs to the protection scope of the invention:
the application of the protein in preparing anti-rotavirus serum;
p2. the use of said protein in the preparation of rotavirus antibodies;
and P3, the protein is applied to the preparation of vaccines against rotavirus.
The application of the biological material related to the protein in the invention in any one of the following Q1-Q3 also falls within the protection scope of the invention:
q1. application of the biological material in preparing anti-rotavirus serum;
the application of the biological material in preparing rotavirus antibodies;
q3. application of the biological material in preparing vaccines against rotavirus.
The invention provides a preparation method of anti-rotavirus serum, which comprises the step of immunizing animals by using the protein to obtain the anti-rotavirus serum.
The application of the preparation method of the anti-rotavirus serum in any one of the following R1-R3 also belongs to the protection scope of the invention:
r1. the application of the preparation method in preparing anti-rotavirus serum;
r2. the preparation method is applied to the preparation of rotavirus antibodies;
and R3, the preparation method is applied to preparation of rotavirus resisting vaccines.
The invention has the beneficial effects that: a recombinant protein VP7, a truncation of a main antigen of an HRV epidemic strain, is provided, the recombinant protein VP7 has no cytotoxicity, and the protective titer of a neutralizing antibody for protecting cells from infection of rotavirus RF strain (G6P [1 ]) is detected to be 1:21.97 by using an antibody delta VP7 obtained by immunizing rabbits with the recombinant protein VP7 (delta VP 7). The VP7 recombinant protein provides a molecular basis for designing a recombinant subunit vaccine through the antigen and preventing the infection of HRV epidemic strains at the present stage.
Drawings
FIG. 1 Western results of GST (glutathione mercaptotransferase) induced expression.
FIG. 2 Western results of expression induction by Transetta (DE3) -. DELTA.VP 7-1.
FIG. 3 Western results of expression induction by Transetta (DE3) -. DELTA.VP 7-9.
FIG. 4 Western results of expression induction by Transetta (DE3) -. DELTA.VP 7-10, and by Transetta (DE3) -. DELTA.VP 7-11.
FIG. 5 Western results of inducible expression of Transetta (DE3) -. DELTA.VP 7-12.
FIG. 6 Western results of inducible expression by Transetta (DE3) -. DELTA.VP 7-15 and Transetta (DE3) -. DELTA.VP 7-16.
FIG. 7 is a schematic diagram of Δ VP7, gray for non-toxic recombinant protein and black for toxic recombinant protein, wherein the toxic region is 284-322 amino acid fragment.
FIG. 8 Western results of the induction of expression of recombinant protein Δ VP 7.
Detailed Description
The present invention is described in further detail below with reference to specific embodiments, which are given for the purpose of illustration only and are not intended to limit the scope of the invention. The examples provided below serve as a guide for further modifications by a person skilled in the art and do not constitute a limitation of the invention in any way.
The experimental procedures in the following examples, unless otherwise indicated, are conventional and are carried out according to the techniques or conditions described in the literature in the field or according to the instructions of the products. Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
Example 1 construction of VP7 and Δ VP7
The complete gene sequence of VP7 of BJ-Q794 is synthesized (the sequence synthesis is entrusted to Shanghai Jie biological engineering Co., Ltd.), the amino acid sequence of VP7 is shown as the sequence 2 in the sequence table, and the complete gene (nucleotide) sequence of VP7 is shown as the sequence 1 in the sequence table. The entire gene sequence of VP7 was inserted between SmaI and SalI sites of pGH vector (Shanghai Czejust bioengineering, Ltd.) while keeping the other sequences of pGH vector unchanged to obtain recombinant plasmid pGH-J1-VP 7. HRV epidemic strain BJ-Q794 (genotype G9P [8], GenBank sequence number: KF673438) is the target strain (reference: royal jelly et al, G9-VI rotavirus reappeared and predominance in children with Beijing diarrhea, Virol, 2016,32 (4): DOI:10.13242/j.cnki. bindduxuebao.002983).
According to the structural analysis of VP7 protein, a series of truncations are designed, which are respectively delta VP7-1, delta VP7-2, delta VP7-3, delta VP7-4, delta VP7-5, delta VP7-6, delta VP7-7, delta VP7-8, delta VP7-9, delta VP7-10, delta VP7-11, delta VP7-12, delta VP7-13, delta VP7-14, delta VP7-15, delta VP7-16, delta VP7-17 and delta VP7, wherein the amino acid sequence of delta VP7-1 is the 55-326 th position of sequence 1, the amino acid sequence of VP7-2 is the 51-326 th position of sequence 1, the amino acid sequence of delta VP7-3 is the 58-326 th position of sequence 1, the amino acid sequence of delta 7-4 is the 51-326 th position of sequence 865-327 of sequence 861, the amino acid sequence of the delta VP7-6 is the 109-326 th position of the sequence 1, the amino acid sequence of the delta VP7-7 is the 51-322 th position of the sequence 1, the amino acid sequence of the delta VP7-8 is the 109-215 th position of the sequence 1, the amino acid sequence of the delta VP7-9 is the 216-322 th position of the sequence 1, the amino acid sequence of the delta VP7-10 is the 216-265 th position of the sequence 1, the amino acid sequence of the delta VP7-11 is the 266-322 th position of the sequence 1, the amino acid sequence of the delta VP7-12 is the 266-322 th position of the sequence 1, the amino acid sequence of the delta VP7-13 is the 293-322 th position of the sequence 1, the amino acid sequence of the delta VP7-14 is the 284-322 th position of the sequence 1, the amino acid sequence of the delta VP7-15 is the 284-304 th position of the sequence 1, and the amino acid sequence of the delta VP7-16 is the 284-312 st position of the 284-312, the amino acid sequence of delta VP7-17 is 51-265 th position of sequence 1, the amino acid sequence of delta VP7 is 51-283 th position of sequence 1, and the designed primers corresponding to the above-mentioned short truncations are shown in Table 1. Recombinant plasmid pGH-J1-VP7 is used as a template, and primer pairs in Table 1 are respectively used as primers for amplification to obtain amplification products VP7, delta VP7-1, delta VP7-2, delta VP7-3, delta VP7-4, delta VP7-5, delta VP7-6, delta VP7-7, delta VP7-8, delta VP7-9, delta VP7-10, delta VP7-11, delta VP7-12, delta VP7-13, delta VP7-14, delta VP7-15, delta VP7-16, delta VP7-17 and delta VP 7. The resulting amplified products were used to replace the sequence between the XmaI and EcoRI recognition sites in pGEX-3X vector (GE Co.) and the other sequences of pGEX-3X vector were kept unchanged, resulting in recombinant vectors pGEX-3X-VP7, pGEX-3X- Δ VP7-1, pGEX-3X- Δ VP7-2, pGEX-3X- Δ VP7-3, pGEX-3X- Δ VP7-4, pGEX-3X- Δ VP7-5, pGEX-3X- Δ VP7-6, pGEX-3X- Δ VP7-7, pGEX-3X- Δ VP7-8, pGEX-3X-VP 7-9, pGEX-3X- Δ VP7-10, pGEX-3X-VP 7-11, pGEX-3X-7-12, pGEX-3X-delta VP7-13, pGEX-3X-delta VP7-14, pGEX-3X-delta VP7-15, pGEX-3X-delta VP7-16, pGEX-3X-delta VP7-17 and pGEX-3X-delta VP7, each recombinant vector can express a fusion protein formed by fusing a VP7 protein or a corresponding VP7 protein truncation at the N end with a GST tag; the recombinant vectors pGEX-3X-VP7, pGEX-3X-delta VP7-1, pGEX-3X-delta VP7-2, pGEX-3X-delta VP7-3, pGEX-3X-delta VP7-4, pGEX-3X-delta VP7-5, pGEX-3X-delta VP7-6, pGEX-3X-delta VP7-7, pGEX-3X-delta VP7-8, pGEX-3X-delta VP7-9, pGEX-3X-delta VP7-10, pGEX-3X-delta VP7-11, pGEX-3X-VP 7-12, pGEX-3X-delta VP7-13, pGEX-3X-delta VP7-14, pGEX-3X-delta VP7-15, pGEX-3X- Δ VP7-16, pGEX-3X- Δ VP7-17 and pGEX-3X- Δ VP7 Escherichia coli Trans10 (Beijing Quanjin Biotechnology Co., Ltd.) was transformed to obtain a series of recombinant plasmids carrying the correct Δ VP7 sequence, each of which was transformed into Escherichia coli Transetta (DE3) (Beijing Quanjin Biotechnology Co., Ltd.) and was Escherichia coli Transetta (DE3) -VP7, Transetta (DE3) -. DELTA VP7-1, Transetta (DE3) -. DELTA VP 42-2, Transetta (DE3) -. DELTA VP7-3, Transetta (DE3) -. VP7-4, Transetta (DE3) -. DELTA. 7-5, Transetta (DE 3. DELTA.). VP7-6, Transetta (DE-3) -. DELTA.) -7, Transetta (VP 363672) -. DELTA.) -363672, and a sequence of Escherichia coli Transetta, Transetta (DE3) -. DELTA.VP 7-10, Transetta (DE3) -. DELTA.VP 7-11, Transetta (DE3) -. DELTA.VP 7-12, Transetta (DE3) -. DELTA.VP 7-13, Transetta (DE3) -. DELTA.VP 7-14, Transetta (DE3) -. DELTA.VP 7-15, Transetta (DE3) -. DELTA.VP 7-16, Transetta (DE3) -. DELTA.VP 7-17 and Transetta (DE3) -. DELTA.VP 7, which are used as host bacteria for inducible expression of fusion proteins.
TABLE 1 PCR primers expressing VP7 and Δ VP7
Figure BDA0002764440990000051
Figure BDA0002764440990000061
Example 2 inducible expression of the VP7 and Δ VP7 fusion proteins
1. Escherichia coli Transetta (DE3) -VP7 prepared in example 1 was cultured in LB liquid medium at 220rpm at 37 ℃ overnight (16 hours). Transferred into 500ml of fresh medium according to the ratio of 1:1000Continuing to culture to OD600Between about 0.35 and 0.5, isopropyl-. beta. -D-thiogalactoside (IPTG) was added to induce at a final concentration of 0.1 mM. The method for inducing expression of the fusion protein comprises the following steps: the cells were cultured at 37 ℃ and 220rpm for 4 hours under induction, and the precipitated cells were collected by centrifugation at 4 ℃ and prepared for extraction of the fusion protein.
2. The method for inducing expression of the fusion protein in the step 1 is replaced by the following steps: the cells were cultured overnight (16 hours) at 16 ℃ and 180rpm, and the precipitated cells were collected by centrifugation at 4 ℃ and prepared for extraction of the fusion protein. The other steps are unchanged.
3. Adding PBS buffer solution into the thallus obtained in the step 1 or 2 for fully suspending, adding a loading buffer solution (Bio-rad, cat number: 1610747) of 4 xSDS-PAGE, boiling in water bath for 5min for lysing the thallus, centrifugally collecting supernatant containing the fusion protein, performing gel separation on the protein through SDS-PAGE, and detecting the protein expression condition through Western blots. The primary antibody of Western blots was Rabbit polyclonal to GST (Abcam, cat # ab19256) at 1:1000 dilution. The secondary antibody was Anti-Rabbit IgG (H + L), HRP Conjugate (Promega, cat # W4011), 1:1000 dilution. The development was carried out using a chemiluminescent substrate (Thermo Fisher, SuperSignal West Dura, cat. No.: A38555).
The Escherichia coli Transetta (DE3) -VP7 in the steps 1-3 is sequentially replaced by Escherichia coli Transetta (DE3) -. DELTA.VP 7-1, Transetta (DE3) -. DELTA.VP 7-2, Transetta (DE3) -. DELTA.VP 7-3, Transetta (DE3) -. DELTA.VP 7-4, Transetta (DE3) -. DELTA.VP 7-5, Transetta (DE3) -. DELTA.VP 7-6, Transetta (DE3) -. DELTA.VP 7-7, Transetta (DE3) -. DELTA.VP 7-8, Transetta (DE3) -. DELTA.VP 7-9, transetta (DE3) -. DELTA.VP 7-10, Transetta (DE3) -. DELTA.VP 7-11, Transetta (DE3) -. DELTA.VP 7-12, Transetta (DE3) -. DELTA.VP 7-13, Transetta (DE3) -. DELTA.VP 7-14, Transetta (DE3) -. DELTA.VP 7-15, Transetta (DE3) -. DELTA.VP 7-16, Transetta (DE3) -. DELTA.VP 7-17 or Transetta (DE3) -. DELTA.VP 7). The other steps are unchanged.
The results are shown in FIGS. 1 to 6, and FIG. 1 shows the Western blot results of GST (glutathione mercaptotransferase) -induced expression. Wherein the bacterial cells (Transetta (DE3) -VP7) are induced at 37 ℃ and the primary antibody is GST antibody. The arrow indicates the GST protein, 26.6kDa in size. Lanes 1, 2 are: not inducing thallus holoprotein, inducing thallus holoprotein. FIG. 2 shows the Western blot results of inducible expression of Transetta (DE3) -. DELTA.VP 7-1. In the A and B panels, the cells were induced at 37 deg.C (A) and 16 deg.C (B), respectively, and the primary antibody was GST antibody. The arrow indicates the fusion protein Δ VP7-1 fused to the GST tag, with a size of 57.5 kDa. Lanes 1-6 are: non-induced thallus soluble protein, non-induced thallus insoluble protein, non-induced thallus total protein, induced thallus soluble protein, induced thallus insoluble protein and induced thallus total protein. FIG. 3 shows the Western blot results of Transetta (DE3) -. DELTA.VP 7-9 induced expression. Wherein the bacteria are induced at 37 deg.C and 16 deg.C respectively, and the primary antibody is GST antibody. The arrow indicates a 38.8kDa Δ VP7-9 fusion protein fused to a GST tag. Lanes 1-4 are: the whole protein of the thallus is not induced at 37 ℃, the whole protein of the thallus is not induced at 16 ℃ and the whole protein of the thallus is induced at 16 ℃. FIG. 4 shows Western blot results of inducible expression by Transetta (DE3) -. DELTA.VP 7-10 and Transetta (DE3) -. DELTA.VP 7-11. Wherein the bacteria are induced at 37 deg.C and 16 deg.C respectively, and the primary antibody is GST antibody. Arrows in lanes 1-4 show the Δ VP7-10 fusion protein fused to the GST tag, with a size of 32.0 kDa. Arrows in lanes 5-8 show the Δ VP7-11 fusion protein fused to the GST tag, with a size of 32.0 kDa. Lanes 1-4, 5-8 are: the whole protein of the thallus is not induced at 37 ℃, the whole protein of the thallus is not induced at 16 ℃ and the whole protein of the thallus is induced at 16 ℃. FIG. 5 shows the Western blot results of inducible expression of Transetta (DE3) -. DELTA.VP 7-12. Wherein the bacteria are induced at 37 deg.C and 16 deg.C respectively, and the primary antibody is GST antibody. The arrow indicates the fusion protein Δ VP7-12 fused to the GST tag, which is 29.8kDa in size. Lanes 1-3 are: not inducing thallus holoprotein at 37 ℃, inducing thallus holoprotein at 37 ℃ and inducing thallus holoprotein at 16 ℃. FIG. 6 shows Western blot results of inducible expression by Transetta (DE3) -. DELTA.VP 7-15 and Transetta (DE3) -. DELTA.VP 7-16. Wherein the bacteria are induced at 37 deg.C and 16 deg.C respectively, and the primary antibody is GST antibody. Arrows in lanes 1-3 show the Δ VP7-15 fusion protein fused to the GST tag, and has a size of 29.4 kDa. Arrows in lanes 4-6 show the Δ VP7-16 fusion protein fused to the GST tag, with a size of 30.3 kDa. Lanes 1-3, 4-6 are: not inducing thallus holoprotein at 37 ℃, inducing thallus holoprotein at 37 ℃ and inducing thallus holoprotein at 16 ℃. Lane 7 is the GST-induced whole cell protein at 37 ℃
After the VP7 and each delta VP7 fusion protein are induced to express, the growth of the host bacteria is judged for cytotoxicity. OD of host bacteria before and after induction expression of VP7 and each delta VP7 fusion protein600The measurements are shown in Table 2:
TABLE 2 various Δ G9P [8]]Post-induction OD of VP7 protein600
Figure BDA0002764440990000081
Figure BDA0002764440990000091
As can be seen from the results in Table 2, only the Δ VP7-8(109-600Significantly increased) indicating that the short truncates Δ VP7-8(109-215), Δ VP7-10(216-265), Δ VP7-12(266-292) and Δ VP7 (51-283) are not cytotoxic, and that the other short truncates are cytotoxic, as shown in FIG. 7. FIG. 7 shows the respective Δ VP7 truncated sequences, wherein grey indicates the non-toxic recombinant protein and black indicates the toxic recombinant protein, wherein the toxic region is the 284-322 amino acid fragment.
Example 3 purification of Δ VP7 fusion protein, antibody preparation and antibody titer detection
1. Escherichia coli prepared in example 1 was cultured in Transetta (DE3) -. DELTA.VP 7 in LB liquid medium at 220rpm at 37 ℃ overnight (16 hours). Transferring the culture medium into a fresh culture medium according to the ratio of 1:1000, and continuing culturing until OD is reached600Between about 0.35 and 0.5, isopropyl-. beta. -D-thiogalactoside (IPTG) was added to induce at a final concentration of 0.1 mM. The method for inducing expression comprises the following steps: the cells were cultured overnight (16 hours) at 16 ℃ and 180rpm, and the precipitated cells were collected by centrifugation at 4 ℃ and prepared for extraction of the fusion protein Δ VP 7.
2. The cells (500ml) were collected by centrifugation, resuspended in PBS containing protease inhibitors, the supernatant removed by centrifugation, resuspended again in 20ml PBS containing protease inhibitors and placed on ice.
3. The thalli is crushed by a low-temperature ultrahigh-pressure continuous flow cell crusher.
4. The soluble protein was collected by centrifugation.
5. Protein purification was performed by GST tag, protein was purified by a Glutathione Sepharose 4 Fast Flow (GE Healthcare, 17-5132-01) gel column, target protein was eluted with 50mM Tris-HCl pH 8.0 containing 20mM reduced Glutathione, target protein was concentrated by ultrafiltration, and the protein storage solution was changed to PBS solution, thereby obtaining GST-. DELTA.VP 7 solution. The protein purity was 85% and was quantified by bradford assay.
The fusion protein (GST-delta VP7) expressed in E.coli was fused with the N-terminal GST tag by the delta VP7 (26 kDa) shown in positions 51-283 of SEQ ID NO. 2, and was 26.88kDa in size and 52.58kDa in size of GST-delta VP 7. GST- Δ VP7 was 85% pure, as shown in FIG. 8. 500ml of E.coli suspension was purified to obtain 0.75mg of GST- Δ VP 7-fusion protein.
6. Purified GST-delta VP7 immune rabbit (animal technology limited, Kyowa laboratory, Beijing) was used to prepare antibody (immune experiment was performed in the center of the institute of genetics and developmental biology, China academy of sciences), immunization was performed in four times, the first immunization was performed with a mixed solution obtained by mixing 1:1 volume of GST-delta VP7 obtained in step 5 with complete Freund's adjuvant (Sigma Co.), the amount of GST-delta VP7 was 0.5mg, the second immunization was performed with a mixed solution obtained by mixing 1:1 volume of incomplete Freund's adjuvant (Sigma Co.) with the GST-delta VP7 obtained in step 5, the amount of GST-delta VP7 was 0.25mg, the third immunization was performed with 1:1 volume of incomplete Freund's adjuvant (Sigma Co.), the mixed solution obtained by mixing 1:1 volume of GST-delta VP7 obtained in step 5 with GST-delta VP7 mg, the amount of GST-delta VP7 mg, the third immunization was performed with 1:1 volume of incomplete GST-delta VP7 mg Delta VP7 solution was mixed to obtain a mixture, GST-delta VP7 was used in an amount of 0.5mg, the time interval between immunizations was 14 days, and blood was taken from carotid artery by intubation 3 weeks after the last immunization to obtain serum.
7. The resulting serum was tested for neutralizing antibody titer:
1) MA104 cells (monkey fetal kidney cells) were passaged into 96-well plates and cultured for 16-20 hours.
2) Test serum was taken, subjected to water bath at 60 ℃ for 30min to inactivate complement, and then diluted 4-fold in a gradient in MEM medium containing 2. mu.g/ml of pancreatin to give each serum dilution.
3) Taking rotavirus RF strain (G6P [1]]Type) (described in James E Richards, Ulrich Desselberger, Andrew M Lever. Experimental products of surgery reduction a rotaviruses genes system: synthetic full length peptides of surgery were each isolated in vitro cells plos one.8(9): e74328, 2013.) EDTA-free pancreatic enzyme was added to a concentration of 10. mu.g/ml, followed by incubation at 37 ℃ for 1 hour and then diluted to 200TCID with MEM medium containing 2. mu.g/ml pancreatic enzyme50。
4) Mixing the serum diluent obtained in the step 2) and the virus solution obtained in the step 3) in equal volume, and incubating for 1 hour at 37 ℃.
5) After completion of step 1), the cells were washed 3 times with MEM medium, and then 20. mu.l of the mixture obtained in step 4) was added to each well and incubated at 37 ℃ for 1 hour.
6) After completion of step 5), the supernatant was aspirated, and MEM medium containing 2. mu.g/ml of trypsin was added and cultured at 37 ℃ for 3 days.
7) After completion of step 6), the cytopathic condition was observed and the serum neutralizing antibody titer was calculated.
Figure BDA0002764440990000111
lg(TCID50) Logarithm-distance ratio of greater than 50% serum dilution x logarithm of dilution factor ═ n
TCID50＝10n,20μl
10nA serum that is 1: m, i.e. 1: m, protects the cells from disease, i.e. the neutralizing antibody titer of that serum.
The delta VP7 antibody obtained from immunized rabbit, the protective titer of neutralizing antibody for protecting cell from infection of rotavirus RF strain (G6P [1 ]) is 1: 21.97.
The present invention has been described in detail above. It will be apparent to those skilled in the art that the invention can be practiced in a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation. While the invention has been described with reference to specific embodiments, it will be appreciated that the invention can be further modified. In general, this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains. The use of some of the essential features is possible within the scope of the claims attached below.
Sequence listing
<110> plant chain (Shanghai) Biotechnology Ltd
<120> rotavirus VP7 recombinant protein and application thereof
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 981
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
atgtatggta ttgaatatac cacagttcta acctttctga tatcaatagt tttattgaac 60
tacatattaa aatcactaac tagtgcgatg gactttatac tttatagatt tcttttactt 120
attgttattt tgtcgccatt tgtcaaaaca caaaattatg ggataaattt accaattact 180
ggctccatgg acacagtata tgcaaattcg tcacagcaag aaacattttt aacttcaacg 240
ctatgtttat attatcctac tgaagcatca actcaaattg gagatactga atggaagaat 300
actctatctc aattattctt gactaagggg tggccaactg gatcagtcta ttttaaagaa 360
tatacagata tcgcttcatt ctcaattgat ccacaacttt attgtgatta taatgttgtg 420
ctaatgaagc atgattcaac gttagagcta gatatgtcag aattggctga tttgattcta 480
aatgaatggt tatgcaatcc aatggatata acattatatt attatcagca aacagatgaa 540
tcgaataaat ggatatcgat gggacaatct tgtaccataa aagtgtgccc attaaataca 600
caaactttag gaataggttg tactactaca aatacagcga catttgaaga agtagctact 660
agtgagaaat tagtgataac tgatgttgtt gatggcgtga atcataagct tgatgtaact 720
acaaatacct gtacaattag aaattgtaag aagttaggac cgagagaaaa tgtagcaatt 780
atacaagtcg gtggctcaga agtgttagat attacagcgg atccaactac cacaccacaa 840
actgagcgta tgatgcgagt aaattggaag aaatggtggc aagttttcta tacagtagta 900
gattacatta atcagattgt gcaatttatg tccaaaagat cacggtcatt aaattcagca 960
gctttttatt atagagtctg a 981
<210> 2
<211> 326
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Met Tyr Gly Ile Glu Tyr Thr Thr Val Leu Thr Phe Leu Ile Ser Ile
1 5 10 15
Val Leu Leu Asn Tyr Ile Leu Lys Ser Leu Thr Ser Ala Met Asp Phe
20 25 30
Ile Leu Tyr Arg Phe Leu Leu Leu Ile Val Ile Leu Ser Pro Phe Val
35 40 45
Lys Thr Gln Asn Tyr Gly Ile Asn Leu Pro Ile Thr Gly Ser Met Asp
50 55 60
Thr Val Tyr Ala Asn Ser Ser Gln Gln Glu Thr Phe Leu Thr Ser Thr
65 70 75 80
Leu Cys Leu Tyr Tyr Pro Thr Glu Ala Ser Thr Gln Ile Gly Asp Thr
85 90 95
Glu Trp Lys Asn Thr Leu Ser Gln Leu Phe Leu Thr Lys Gly Trp Pro
100 105 110
Thr Gly Ser Val Tyr Phe Lys Glu Tyr Thr Asp Ile Ala Ser Phe Ser
115 120 125
Ile Asp Pro Gln Leu Tyr Cys Asp Tyr Asn Val Val Leu Met Lys His
130 135 140
Asp Ser Thr Leu Glu Leu Asp Met Ser Glu Leu Ala Asp Leu Ile Leu
145 150 155 160
Asn Glu Trp Leu Cys Asn Pro Met Asp Ile Thr Leu Tyr Tyr Tyr Gln
165 170 175
Gln Thr Asp Glu Ser Asn Lys Trp Ile Ser Met Gly Gln Ser Cys Thr
180 185 190
Ile Lys Val Cys Pro Leu Asn Thr Gln Thr Leu Gly Ile Gly Cys Thr
195 200 205
Thr Thr Asn Thr Ala Thr Phe Glu Glu Val Ala Thr Ser Glu Lys Leu
210 215 220
Val Ile Thr Asp Val Val Asp Gly Val Asn His Lys Leu Asp Val Thr
225 230 235 240
Thr Asn Thr Cys Thr Ile Arg Asn Cys Lys Lys Leu Gly Pro Arg Glu
245 250 255
Asn Val Ala Ile Ile Gln Val Gly Gly Ser Glu Val Leu Asp Ile Thr
260 265 270
Ala Asp Pro Thr Thr Thr Pro Gln Thr Glu Arg Met Met Arg Val Asn
275 280 285
Trp Lys Lys Trp Trp Gln Val Phe Tyr Thr Val Val Asp Tyr Ile Asn
290 295 300
Gln Ile Val Gln Phe Met Ser Lys Arg Ser Arg Ser Leu Asn Ser Ala
305 310 315 320
Ala Phe Tyr Tyr Arg Val
325

Claims (10)

1. The application of the protein in any one of the following P1-P3:
the application of the protein in preparing anti-rotavirus serum;
p2. the use of said protein in the preparation of rotavirus antibodies;
the application of the protein in preparing anti-rotavirus vaccine;
the protein is A1) or A2):
A1) VP7 recombinant protein, wherein the VP7 recombinant protein is a short truncation of the amino acid sequence described in sequence 2, and the short truncation does not contain the sequence at position 284-322 in sequence 2;
A2) a1) at the N-terminus or/and the C-terminus.
2. The use of claim 1, wherein the amino acid sequence of the VP7 recombinant protein is the sequence shown at positions 51-283 in SEQ ID NO 2.
3. Use of a biomaterial related to a protein according to claim 1 or 2 in any one of the following Q1-Q3:
q1. application of the biological material in preparing anti-rotavirus serum;
the application of the biological material in preparing rotavirus antibodies;
q3. the use of the biomaterial in the manufacture of a vaccine against rotavirus;
the biological material is shown in any one of the following B1) -B5):
B1) a nucleic acid molecule encoding the protein of claim 1 or 2;
B2) an expression cassette comprising the nucleic acid molecule of B1);
B3) a recombinant vector containing the nucleic acid molecule of B1) or a recombinant vector containing the expression cassette of B2);
B4) a recombinant microorganism containing B1) the nucleic acid molecule, or a recombinant microorganism containing B2) the expression cassette, or a recombinant microorganism containing B3) the recombinant vector;
B5) a transgenic animal cell line containing the nucleic acid molecule according to B1) or a transgenic animal cell line containing the expression cassette according to B2).
4. The use as claimed in claim 3, wherein B1) is a DNA molecule represented by position 151-849 in sequence 1 of the sequence Listing.
5. A protein, wherein said protein is a1) or a 2):
A1) VP7 recombinant protein, wherein the VP7 recombinant protein is a short truncation of the amino acid sequence described in sequence 2, and the short truncation does not contain the sequence at position 284-322 in sequence 2;
A2) a1) at the N-terminus or/and the C-terminus.
6. The protein of claim 5, wherein the amino acid sequence of the VP7 recombinant protein is the sequence shown in positions 51-283 of SEQ ID NO 2.
7. The biological material related to the protein of claim 5 or 6 is any one of the following B1) -B5):
B1) a nucleic acid molecule encoding the protein of claim 5 or 6;
B2) an expression cassette comprising the nucleic acid molecule of B1);
B3) a recombinant vector containing the nucleic acid molecule of B1) or a recombinant vector containing the expression cassette of B2);
B4) a recombinant microorganism containing B1) the nucleic acid molecule, or a recombinant microorganism containing B2) the expression cassette, or a recombinant microorganism containing B3) the recombinant vector;
B5) a transgenic animal cell line containing the nucleic acid molecule according to B1) or a transgenic animal cell line containing the expression cassette according to B2).
8. The biomaterial as claimed in claim 7, wherein B1) is a DNA molecule represented by position 151-849 in sequence 1 of the sequence Listing.
9. A method for preparing anti-rotavirus serum, comprising the step of immunizing an animal with the protein of claim 5 or 6 to obtain anti-rotavirus serum.
10. The use of the preparation method of claim 9 in any one of the following R1-R3:
use of the preparation method of claim 9 in the preparation of anti-rotavirus serum;
use of the preparation method of claim 9 for the preparation of rotavirus antibodies;
use of the preparation method of claim 9 in the preparation of vaccines against rotavirus.
CN202011228737.0A 2020-11-06 2020-11-06 Rotavirus VP7 recombinant protein and application thereof Active CN112552397B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011228737.0A CN112552397B (en) 2020-11-06 2020-11-06 Rotavirus VP7 recombinant protein and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011228737.0A CN112552397B (en) 2020-11-06 2020-11-06 Rotavirus VP7 recombinant protein and application thereof

Publications (2)

Publication Number Publication Date
CN112552397A true CN112552397A (en) 2021-03-26
CN112552397B CN112552397B (en) 2024-02-13

Family

ID=75041500

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011228737.0A Active CN112552397B (en) 2020-11-06 2020-11-06 Rotavirus VP7 recombinant protein and application thereof

Country Status (1)

Country Link
CN (1) CN112552397B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103304671A (en) * 2013-06-06 2013-09-18 黑龙江八一农垦大学 Human rotavirus P[8]deltaVP8*-P[6]deltaVP8* recombinant chimeric protein and application thereof
CN105085639A (en) * 2014-05-21 2015-11-25 厦门大学 Truncated rotavirus VP8 protein and application thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103304671A (en) * 2013-06-06 2013-09-18 黑龙江八一农垦大学 Human rotavirus P[8]deltaVP8*-P[6]deltaVP8* recombinant chimeric protein and application thereof
CN105085639A (en) * 2014-05-21 2015-11-25 厦门大学 Truncated rotavirus VP8 protein and application thereof
WO2015176586A1 (en) * 2014-05-21 2015-11-26 厦门大学 Truncated rotavirus vp8 protein and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCOTT T. AOKI ET AL.: ""Structure of rotavirus outer-layer protein VP7 bound with a neutralizing Fab"", 《SCIENCE》, vol. 324, no. 5933, pages 1 - 9 *
王红涛 等: ""轮状病毒 VP7 糖蛋白基因的克隆及在毕赤酵母菌中的表达及 免疫原性的分析"", 《病毒学报》, vol. 35, no. 5, pages 1 - 7 *

Also Published As

Publication number Publication date
CN112552397B (en) 2024-02-13

Similar Documents

Publication Publication Date Title
WO2022262142A1 (en) Recombinant sars-cov-2 rbd tripolymer protein vaccine capable of generating broad-spectrum cross-neutralization activity, preparation method therefor, and application thereof
Marelli et al. Oral immunization with live Lactococcus lactis expressing rotavirus VP8* subunit induces specific immune response in mice
CN107043408B (en) Antigen-norovirus P-domain monomers and dimers, antigen-norovirus P-particle molecules, and methods of making and using the same
CN102695522B (en) New Human reoviruslike agent strain and vaccine
NO341881B1 (en) Polypeptide, protein, method of preparation of salmonid alphavirus neutralizing antibodies, nucleic acid, carrier, vaccine and diagnostic kit
He et al. Prokaryotic expression and purification of grass carp reovirus capsid protein VP7 and its vaccine potential
CN116019906A (en) Novel coronavirus immunogenic composition, preparation method and application thereof
JP6808650B2 (en) Shortened rotavirus VP4 protein and its application
CN107586322B (en) Infectious bovine rhinotracheitis virus gD protein epitope polypeptide, inhibitor and monoclonal antibody thereof, and application of infectious bovine rhinotracheitis virus gD protein epitope polypeptide and inhibitor and monoclonal antibody
KR20220009960A (en) Recombinant Classical Swine Fever Virus
EP2254993A1 (en) Protein nanocarriers, process for obtaining them and applications
CN103305542A (en) Recombinant phage double expression vector and application
Choi et al. Intranasal administration of an Escherichia coli-expressed codon-optimized rotavirus VP6 protein induces protection in mice
US6673355B1 (en) Rotavirus enterotoxin NSP4 and methods of using same
Tan et al. Antigenicity and immunogenicity of the immunodominant region of hepatitis B surface antigen displayed on bacteriophage T7
CN112812193A (en) Recombinant protein vaccine of norovirus GII.4 type and enterovirus 71 type
CN112552397B (en) Rotavirus VP7 recombinant protein and application thereof
CN113855795B (en) Avian hepatitis E virus ORF2 subunit vaccine
CN112159480B (en) Chicken infectious bursal disease virus multi-antigen epitope protein and application thereof
WO2002036172A2 (en) Rotavirus enterotoxin nsp4 and methods of using same
CN113234654A (en) Recombinant bacillus subtilis and application thereof
CN111560386A (en) Soluble porcine circovirus type 2 Cap protein and application thereof
WO2016186483A1 (en) Sequences of synthetic deoxyribonucleic acids and heterologous recombinant proteins of the haemagglutinin of the influenza virus expressed in chlamydomonas reinhardtii chloroplast, and use thereof in vaccines
CN112251461B (en) Rotavirus vaccine prepared by taking Nicotiana benthamiana as bioreactor as well as preparation method and application thereof
ES2328350T3 (en) INCLUSION BODIES AS ANTIGENS FOR ORAL VACCINATION OF ANIMALS AGAINST VPPC.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant